33.50
-0.43 (-1.27%)
| Penutupan Terdahulu | 33.93 |
| Buka | 34.34 |
| Jumlah Dagangan | 195,128 |
| Purata Dagangan (3B) | 1,217,138 |
| Modal Pasaran | 6,152,241,152 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.00 |
| Harga / Jualan (P/S) | 11.04 |
| Harga / Buku (P/B) | 6.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Keuntungan | -28.22% |
| Margin Operasi (TTM) | -40.19% |
| EPS Cair (TTM) | -0.960 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 134.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 33.69% |
| Nisbah Semasa (MRQ) | 4.62 |
| Aliran Tunai Operasi (OCF TTM) | -144.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -38.58 M |
| Pulangan Atas Aset (ROA TTM) | -10.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -15.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Legend Biotech Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.13 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.33% |
| % Dimiliki oleh Institusi | 55.49% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Morgan Stanley, 138.81%) | Beli |
| Median | 77.50 (131.34%) | |
| Rendah | 75.00 (HC Wainwright & Co., 123.88%) | Beli |
| Purata | 77.50 (131.34%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 38.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 17 Mar 2025 | 80.00 (138.81%) | Beli | 37.94 |
| HC Wainwright & Co. | 12 Mar 2025 | 75.00 (123.88%) | Beli | 38.24 |
| 23 Jan 2025 | 73.00 (117.91%) | Beli | 37.69 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Mar 2025 | Pengumuman | Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights |
| 25 Feb 2025 | Pengumuman | Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |